Lacto-N-fucopentaose III found on Schistosoma mansoni egg antigens functions as adjuvant for proteins by inducing Th2-type response.
We have recently demonstrated that induction of Th2 responses by Schistosoma mansoni egg Ag is largely due to carbohydrates on the Ag functioning as adjuvants. Lacto-N-fucopentaose III (LNFPIII), a polylactosamine sugar, is the predominant carbohydrate found in S. mansoni egg Ag. Therefore, using neoglycoprotein, we investigated whether LNFPIII induces in vivo Th2 response and functions as an adjuvant. Following intranasal immunization with LNFPIII linked to human serum albumin (HSA) (HSA-LNFPIII), BALB/c mice mounted a strong Th2 response and produced significantly higher levels of total IgE as well as HSA-specific IgG, IgG1, and IgE. HSA-LNFPIII was over 1000-fold more potent in inducing Ab production as compared with HSA alone. Although LNFPIII itself did not function as an epitope for either IgG or IgE, its conjugation with protein was essential for the adjuvant activity. Moreover, fucose residue on LNFPIII was crucial for induction of Ab production. Nasal lymphocytes from mice immunized with HSA-LNFPIII produced IL-4, IL-5, and IL-10, but not IFN-gamma following in vitro stimulation with HSA or HSA-LNFPIII. In addition, these activated nasal lymphocytes also showed a significant increase of B7-2 expression on B220-positive cells. Furthermore, not only intranasal but also both i.p. and s.c. immunization with HSA-LNFPIII induced significant production of HSA-specific Abs compared with the immunization with HSA alone, suggesting that the activity of LNFPIII was not restricted on particular route of immunization. These results demonstrate that Lewis type carbohydrate LNFPIII can function as an adjuvant by their ability to induce a Th2 response.
Okano
M
M
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA. mokano@cc.okayama-u.ac.jp
Satoskar
A R
AR
Nishizaki
K
K
Harn
D A
DA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000281:Administration, Intranasal; D000606:Amino Sugars / Q000008:administration & dosage* / Q000276:immunology*; D000818:Animals; D000909:Antibodies, Helminth / Q000096:biosynthesis; D015703:Antigens, CD / Q000096:biosynthesis; D000947:Antigens, Helminth / Q000008:administration & dosage / Q000276:immunology*; D051940:B7-2 Antigen; D016207:Cytokines / Q000096:biosynthesis; D004306:Dose-Response Relationship, Immunologic; D000939:Epitopes / Q000276:immunology; D005260:Female; D006001:Glycoconjugates / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D007274:Injections, Intraperitoneal; D017493:Leukocyte Common Antigens / Q000096:biosynthesis; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009297:Nasal Mucosa / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D009844:Oligosaccharides / Q000008:administration & dosage / Q000276:immunology*; D011134:Polysaccharides / Q000008:administration & dosage* / Q000276:immunology*; D012550:Schistosoma mansoni / Q000276:immunology*; D012709:Serum Albumin / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000606:Amino Sugars; D000909:Antibodies, Helminth; D015703:Antigens, CD; D000947:Antigens, Helminth; D051940:B7-2 Antigen; C497964:CD86 protein, human; C497965:Cd86 protein, mouse; D016207:Cytokines; D000939:Epitopes; D006001:Glycoconjugates; D008562:Membrane Glycoproteins; D009844:Oligosaccharides; D011134:Polysaccharides; D012709:Serum Albumin; C434666:lacto-N-fucopentaose III; D017493:Leukocyte Common Antigens